8-K: Ultragenyx Reports Q1 2026 Results, Reaffirms Guidance

Ultragenyx Pharmaceutical Inc. announced first quarter 2026 financial results, reporting $136 million in total revenue and reaffirming its full-year 2026 revenue guidance of $730 million to $760 million, while providing updates on key clinical programs.

Summary

• Ultragenyx reported first quarter 2026 total revenue of $136 million, a slight decrease from $139 million in the same period last year.
• Crysvita revenue for Q1 2026 was $93 million, and Dojolvi revenue was $18 million.
• The company reaffirmed its full-year 2026 total revenue guidance of $730 million to $760 million.
• Full-year 2026 combined R&D and SG&A expenses are expected to be flat to slightly down compared to 2025, with a projected decrease of at least 15% in 2027.
• Net loss for Q1 2026 was $185 million, or $1.84 per share, compared to a net loss of $151 million, or $1.57 per share, in Q1 2025.
• Cash, cash equivalents, and marketable securities stood at $534 million as of March 31, 2026.
• GTX-102 for Angelman syndrome showed durable and improving effects in longer-term Phase 1/2 data, with Phase 3 data expected in the second half of 2026.
• Two Biologics License Applications (BLAs) are under review: DTX401 for GSDIa with a PDUFA date of August 23, 2026, and UX111 for MPS IIIA with a PDUFA date of September 19, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report, with key clinical trial updates and regulatory milestones being positive, offset by an increased net loss and slight revenue dip year-over-year.

Positives

• Reaffirmed full-year 2026 total revenue guidance of $730 million to $760 million.
• Reaffirmed full-year 2026 Crysvita revenue guidance of $500 million to $520 million.
• Reaffirmed full-year 2026 Dojolvi revenue guidance of $100 million to $110 million.
• GTX-102 for Angelman syndrome demonstrated durable and improving effects in longer-term Phase 1/2 data, with Phase 3 data anticipated in the second half of 2026.
• DTX401 for GSDIa received Priority Review from the FDA with a PDUFA date of August 23, 2026.
• UX111 for MPS IIIA resubmitted BLA accepted for review with a PDUFA date of September 19, 2026.
• DTX301 for OTC deficiency showed statistically significant reduction in plasma ammonia and improved patient global impression scores in Phase 3 study.
• Company remains on track for profitability in 2027.

Negatives

• Net loss increased to $185 million in Q1 2026 from $151 million in Q1 2025.
• Net loss per share increased to $1.84 in Q1 2026 from $1.57 in Q1 2025.
• Total revenue decreased slightly to $136 million in Q1 2026 from $139 million in Q1 2025.
• Operating expenses increased to $305 million in Q1 2026 from $282 million in Q1 2025, including $30 million in restructuring expenses.
• Cash, cash equivalents, and marketable securities decreased to $534 million from $737 million at the end of 2025.

Risks

• Uncertainty of clinical drug development and the lengthy process for obtaining regulatory approvals.
• Risks related to serious or undesirable side effects of product candidates.
• Ability to achieve projected development goals in expected timeframes.
• Reliance on third-party partners for certain activities.
• Limited experience in generating revenue from product sales.
• Product liability lawsuits.
• Fluctuations in buying or distribution patterns from distributors and specialty pharmacies.
• Competition from other therapies or products.

Future Outlook

The company reaffirms its full-year 2026 total revenue guidance of $730 million to $760 million and expects combined R&D and SG&A expenses to be flat to slightly down versus 2025, with a projected decrease of at least 15% in 2027. Ultragenyx remains on path to profitability in 2027.

Management Comments

• This is an important year for Ultragenyx with two BLAs under review and our Angelman Phase 3 readout coming soon.
• We have the opportunity to meaningfully accelerate our consistent commercial revenue growth over the last few years as we prepare for two potential gene therapy approvals and launches in two urgent diseases without any approved therapies.
• The latest long-term GTX-102 Phase 1/2 data further support the potential of the program, as it heads toward Phase 3 results later this year.

Industry Context

StockSavvy.ai notes that Ultragenyx's focus on rare and ultra-rare genetic diseases positions it in a high-growth, high-unmet-need segment of the biopharmaceutical industry. The company's progress with multiple gene therapy candidates and BLA submissions highlights the increasing therapeutic potential and regulatory pathways for advanced genetic treatments.

Comparison to Industry Standards

• The company's revenue guidance of $730 million to $760 million for 2026 places it among mid-cap biopharmaceutical companies with approved products, but its significant R&D investment reflects the typical profile of companies developing novel therapies for rare diseases.
• The net loss of $185 million in Q1 2026 is substantial but common for biopharmaceutical companies in the development and commercialization phase, especially those with multiple late-stage pipeline assets.
• The PDUFA dates for DTX401 (August 23, 2026) and UX111 (September 19, 2026) are within typical review timelines for Priority Review designations.

Stakeholder Impact

• Shareholders: Reaffirmed guidance and positive clinical updates may support stock value, while increased net loss and cash burn require monitoring.
• Patients: Progress in clinical trials and potential approvals for GTX-102, DTX401, and UX111 offer hope for treatments for serious rare diseases.
• Employees: Restructuring expenses indicate potential workforce adjustments, though specific impacts are not detailed.

Next Steps

• Present updated GTX-102 efficacy and safety data at a future scientific meeting.
• Expect Phase 3 Aspire study data for GTX-102 in the second half of 2026.
• Complete enrollment in the Phase 2/3 Aurora study for GTX-102 in the second half of 2026.
• Await FDA decision on DTX401 with PDUFA date of August 23, 2026.
• Await FDA decision on UX111 with PDUFA date of September 19, 2026.
• Expect data from the dose-finding stage of the Cyprus2+ study (UX701) in 2026.
• Begin externally funded Phase 1/2 study for UX016 in the second half of 2026.
• Expect data for DTX301 in the first half of 2027.

Key Dates

Recommendation

The company is making progress on its pipeline with key data readouts and regulatory submissions expected. However, the increased net loss, slight revenue decline, and substantial cash burn necessitate a cautious 'hold' rating until further clarity on commercial success and profitability is achieved.

Keywords

Ultragenyx, Rare Diseases, Biopharmaceutical, Financial Results, Angelman Syndrome, Gene Therapy, Clinical Trials, FDA